

## Active Products

## Populations

## Locations

## Study Design

## Study Steps



Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral TDF/FTC



About 3,200 cisgender women



Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda, Zimbabwe



### Superiority of CAB LA to TDF/FTC

A superiority study tests whether one drug works better than another drug

#### STEP 1

Two daily oral pills for 5 weeks – 1 active and 1 placebo



#### STEP 2

An injection every 8 weeks and a daily pill for up to 3.5 years



#### STEP 3

A daily oral pill for up to 1 year



# HPTN 084-01

Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral TDF/FTC



About 50 cisgender female adolescents



South Africa, Uganda, Zimbabwe



### Safety, Tolerability and Acceptability of CAB LA

A safety study evaluates the safety of a drug and identifies its side effects

#### STEP 1

A daily oral pill for 5 weeks



#### STEP 2


An injection every 8 weeks for 29 weeks



#### STEP 3

A daily oral pill for 48 weeks



 = placebo